R
Retina Consultants of Hawaii | Aiea, HI
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Ranibizumab
EYP-1901
Aflibercept
Triamcinolone Acetonide
Faricimab
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 8 total trials
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901
Trial sponsors
4
E
L
T
G
R
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems